Ki67 has been identified as a prognostic and predictive marker for breast cancer and it was suggested that it may contribute to pathologic complete response (pCR) after neoadjuvant chemotherapy. It is unclear whether expression of Ki67 is particularly helpful for prediction of pCR across tumor subtypes.
Pretherapeutic Ki67 was evaluated in a series of 121 breast cancer core biopsies. After neoadjuvant chemotherapy, we used postoperative specimens to evaluate the pCR status. Several parameters predictive of pCR were identified using logistic regression analysis. We investigated subgroups defined by estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2, in which predicting pCR with Ki67 might be feasible.
Ki67 was found to be an independent predictor of pCR in multivariate analysis (odds ratio [OR], 3.62; 95% CI, 1.21–10.8). When stratified by ER, the above significance was exclusive to ER-positive tumors (OR, 6.24; 95% CI, 1.40–27.7). Using an receiver-operating characteristic curve, we obtained moderate discriminative accuracy with an area under the curve of 0.7752 for Ki67 prediction of pCR in ER-positive tumors. In subgroup analysis, patients with high Ki67 showed significantly improved pCR rate in luminal-type disease, with a median Ki67 value of 43% in the patients who achieved pCR, versus 29% for those without pCR (P = .018), whereas no associations were observed in other subtypes.
Our results suggest that stratification according to Ki67 levels might improve predictive significance of the response in hormone-responsive breast cancer. Even in these subtypes assumed to be less chemosensitive, some patients with highly proliferative tumors derive a significant benefit from chemotherapy, and consequently it is important to identify them.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes.Cytometry. 1991; 12: 42-49
- Ki67 in breast cancer: prognostic and predictive potential.Lancet Oncol. 2010; 11: 174-183
- Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst. 2009; 101: 736-750
- Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?.Ann Oncol. 2005; 16: 1723-1739
- Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.Breast Cancer. 2012; 20: 262-270
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.Br J Cancer. 2007; 96: 1504-1513
- Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol. 2011; 22: 1736-1747
- Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.Eur J Cancer. 2004; 40: 205-211
- Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.Breast Cancer Res Treat. 2003; 78: 97-103
- Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.Breast Cancer Res Treat. 2012; 131: 827-836
- Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.Ann Oncol. 2013; 24: 2786-2793
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol. 2012; 30: 1796-1804
- Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol. 2008; 26: 1275-1281
- Breast cancer molecular subtypes respond differently to preoperative chemotherapy.Clin Cancer Res. 2005; 11: 5678-5685
- Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.Clin Cancer Res. 2004; 10: 6622-6628
- A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.Eur J Cancer. 2010; 46: 2216-2224
- Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.Br J Cancer. 2003; 88: 406-412
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.J Natl Cancer Inst. 2011; 103: 1656-1664
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004; 351: 2817-2826
- Gene expression profiling predicts clinical outcome of breast cancer.Nature. 2002; 415: 530-536
- Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol. 2009; 27: 1160-1167
- A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.Clin Cancer Res. 2010; 16: 5222-5232
- Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.J Clin Oncol. 2011; 29: 4273-4278
- Evaluation of biological pathways involved in chemotherapy response in breast cancer.Breast Cancer Res. 2008; 10: R37
- Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.Br J Cancer. 2012; 106: 1798-1806
- Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.Breast Cancer Res Treat. 2010; 119: 315-323
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.BMC Cancer. 2011; 11: 486
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol. 2007; 25: 5287-5312
- Proliferation marker Ki-67 in early breast cancer.J Clin Oncol. 2005; 23: 7212-7220
- Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.Breast Cancer Res Treat. 2013; 140: 63-71
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.J Clin Oncol. 2005; 23: 3676-3685
- Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.J Clin Oncol. 2010; 28: 2024-2031
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet. 2010; 375: 377-384
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.Breast Cancer Res Treat. 2011; 125: 145-156
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.Eur J Cancer. 2012; 48: 3342-3354
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.Breast Cancer Res. 2008; 10: R65
- Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.Clin Cancer Res. 2008; 14: 5158-5165
- A consensus prognostic gene expression classifier for ER positive breast cancer.Genome Biol. 2006; 7: R101
Published online: February 07, 2014
Accepted: January 31, 2014
© 2014 Mosby, Inc. Published by Elsevier Inc. All rights reserved.